Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine

Clinical Neuropharmacology

Volumn 32, Issue 2, 2009, Pages 113-116

  Mizuno, Toshiki ^a   Kondo, Masaki ^a   Ishigami, Noriko ^a   Tamura, Aiko ^a   Itsukage, Masahiro ^a   Koizumi, Hideyuki ^a   Isayama, Reina ^a   Hosomi, Akiko ^a   Nagakane, Yoshinari ^a   Tokuda, Takahiko ^a   Sugimoto, Eizo ^a   Ushijima, Yo ^a   Nakagawa, Masanori ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Acetazolamide; CADASIL; IMP SPECT; Lomerizine

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; DIPYRIDAMOLE; ETIZOLAM; IOFETAMINE I 123; LANSOPRAZOLE; LOMERIZINE; LOSARTAN; MAPROTILINE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BRAIN PERFUSION; BRAIN SCINTIANGIOGRAPHY; CADASIL; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DIFFUSION WEIGHTED IMAGING; DRUG WITHDRAWAL; FEMALE; HUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNSPECIFIED SIDE EFFECT;

AMPHETAMINE; CADASIL; CALCIUM CHANNEL BLOCKERS; CEREBRAL CORTEX; COGNITION DISORDERS; DIFFUSION MAGNETIC RESONANCE IMAGING; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; IODINE ISOTOPES; MIDDLE AGED; PIPERAZINES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 67749086625     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31816c82a6     Document Type: Article

References (16)

1. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-710.
2. Hara H, Shimazawa M, Hashimoto M, et al. Anti-migraine effects of lomerizine. Nippon Yakurigaku Zasshi 1998;112(suppl 1): 138P-142P.
3. 2+ channel blocker, on cerebral blood flow in rats and dogs. Clin Exp Pharmacol Physiol 1999;26:870-876.
4. Iida H, Itoh H, Nakazawa M, et al. Quantitative mapping of regional cerebral blood flow using iodine-123-IMP and SPECT. J Nucl Med 1994;35:2019-2030.
5. Forteza AM, Brozman B, Rabinstein AA, et al. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology 2001;57:2144-2145.
6. Chabriat H, Pappata S, Ostergaard L, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 2000;31:1904-1912.
7. Yamashita A, Ozaki A, Ikegami A, et al. Effects of a new diphenylpiperazine calcium antagonist, KB-2796, on cerebral ischemic neuronal damage in rats. Gen Pharmacol 1993;24:1473-1480.
8. Peters N, Herzog J, Opherk C, et al. A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke 2004;35:1603-1608.
9. Markus HS, Lythgoe DJ, Ostegaard L, et al. Reduced cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based perfusion MRI. J Neurol Neurosurg Psychiatry 2000;69:48-53.
10. O'Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002;59:321-326.
11. Yamaguchi S, Fukuyama H, Yamauchi H, et al. Hemodynamics in the cerebral cortex and basal ganglia - observation on normal volunteers and patients with lacunes using PET. Rinsho Shinkeigaku 1991;31:1070-1076.
12. Kitamura S, Terashi A, Araki T, et al. Cerebral hemodynamics in multiple cerebral infarction with or without dementia. Nippon Ronen Igakkai Zasshi 1989;26:557-562.
13. 2+ antagonist, KB-2796, on the regional cerebral blood flow and somatosensory evoked potentials in the ischemic brain in cats. Surg Neurol 1988;30:89-96.
14. 2+ currents and oxidative metabolism in dissociated mammalian CNS neurons. Brain Res 1993;619:263-270.
15. Hara H, Yokota K, Shimazawa M, et al. Effect of KB-2796, a new diphenylpiperazine Ca2+ antagonist, on glutamate-induced neurotoxicity in rat hippocampal primary cell cultures. Jpn J Pharmacol 1993;61:361-365.
16. Wadworth AN, McTavish D. Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders. Drugs Aging 1992;2:262-286.